GRAd-COV2

GRAd-COV2
Vaccine description
TargetSARS-CoV-2
Vaccine typeViral vector
Clinical data
Routes of
administration		Intramuscular

GRAd-COV2 is a COVID-19 vaccine candidate developed by ReiThera Srl and Lazzaro Spallanzani National Institute for Infectious Diseases.[1][2] It is based on a novel replication defective Gorilla Adenovirus and encodes for SARS-COV-2 full length prefusion stabilized Spike protein.[1] More specifically, the vector used is the simian group C adenovirus GRAd32, isolated from a captive gorilla, with a genome deleted of the entire E1 and E3 regions and the native E4 region replaced with the E4 orf6 of human adenovirus 5 (hAd5).[3]

References

  1. 1 2 "GRAd-COV2 Vaccine Against COVID-19". ClinicalTrials.gov. United States National Library of Medicine. 7 January 2021. NCT04528641.
  2. ↑ "ReiThera Announces its GRAd-COV2 COVID-19 Vaccine Candidate is Well Tolerated and Induces Clear Immune Responses in Healthy Subjects Aged 18–55 Years". ReiThera Srl. Yahoo! Finance. 24 November 2020. Retrieved 12 January 2021.
  3. ↑ Capone S, Raggioli A, Gentile M, Battella S, Lahm A, Sommella A, et al. (April 2021). "Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19". Molecular Therapy. 29 (8): 2412–2423. doi:10.1016/j.ymthe.2021.04.022. PMC 8062434. PMID 33895322.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.